Doximity (DOCS) Q1 2027 Earnings Call Transcript
Doximity (DOCS) reported Q1 FY2027 revenue of $156.6 million, up 7% year over year, with adjusted EBITDA of $74.8 million. The company raised full-year 2027 revenue guidance to $671 million to $681 million and adjusted EBITDA guidance to $309 million to $329 million. It also repurchased $91.6 million of stock and ended June 30 with $688 million cash and marketable securities.
How this was made
The 30-second read
Why it matters
Raised FY2027 revenue and adjusted EBITDA guidance, alongside detailed operating metrics (workflow prescribers, prompt volume, scribe users) and margin/FCF drivers, create a clear re-rating setup for DOCS while also introducing near-term uncertainty from tough comps and higher AI compute costs.
Market read
Traders can update DOCS expectations using the raised FY2027 revenue and EBITDA ranges, the Q2 revenue outlook, and the stated drivers of margin and cash flow.
What to watch
The transcript flags hospital AI liability concerns and a shift in AI search revenue recognition starting in Q3, which could create quarter-to-quarter volatility in reported growth and bookings-to-revenue conversion.
Background
Doximity reported Q1 2027 results and discussed clinical AI product traction (AI search, AI scribe) and enterprise security demand during its earnings call.
Ticker impact
Doximity raised FY2027 revenue guidance to $671M-$681M and revised FY2027 adjusted EBITDA to $309M-$329M, plus detailed AI product adoption metrics.
Likely positive bias for DOCS on guidance and adoption metrics, with potential pullback risk if investors focus on FCF decline and margin compression.
The article provides multiple new, decision-relevant datapoints: raised revenue and EBITDA ranges, FQ2 revenue outlook, margin drivers (AI compute), and capital return (buybacks). However, it is a transcript summary and lacks consensus/estimate context, limiting precision on magnitude of repricing.
Market effects
Reinforces the enterprise clinical AI monetization narrative (secure AI agreements, workflow integration) and highlights cost/margin tradeoffs from AI compute spend.
No specific regional market catalyst beyond US healthcare IT spending commentary.
Limited direct global impact; story is primarily US healthcare provider and pharma subscription dynamics.
Counterpoint
Investors may discount the AI adoption metrics if margin compression from AI compute and the 34% YoY FCF decline signal that profitability quality is deteriorating.
Key entities
- companyDoximity
Digital platform for medical professionals; reported Q1 2027 results and raised FY2027 guidance tied to clinical AI adoption.
- executiveJeffrey Tangney
CEO who discussed AI safety performance and enterprise AI steering committee concerns.
- executiveMatthew Sonefeldt
CFO who provided guidance ranges and explained margin and FQ2 growth outlook drivers.
